Search Medical Condition
Please enter condition
Please choose location

Hachinohe-shi, Japan Clinical Trials

A listing of Hachinohe-shi, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (5) clinical trials

A Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Asian Subjects (>=16 to 80 Years of Age) With Epilepsy

The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in Asian subjects (>=16 to 80 years of age) with partial seizures with or without secondary generalization despite current treatment with 1 or 2 concomitant antiepileptic drugs (AEDs) and to ...

Phase

0.0 miles

Learn More »

Specified Drug Use-Results Survey of Regnite

Sleeping condition and severity of restless legs syndrome (RLS) were recorded at the start and during the treatment. The treatment period is scheduled to last 52 weeks in principle. For patients completing or discontinuing the use of Regnite® within 52 weeks, follow up on the withdrawal and rebound syndrome will ...

Phase N/A

2.16 miles

Learn More »

Specified Drug Use-results Survey of Betanis Tablets

To investigate the effects of mirabegron on the symptoms of glaucoma in overactive bladder (OAB) patients with coexisting glaucoma.

Phase N/A

2.16 miles

Learn More »

Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer) Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis

To evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.

Phase N/A

2.16 miles

Learn More »

A Study to Evaluate the Efficacy Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

The purpose of this study is to evaluate the efficacy of fixed dosed intranasal esketamine compared to intranasal placebo, as an add-on to an oral antidepressant in Japanese participants with treatment-resistant depression (TRD), in improving depressive symptoms.

Phase

2.42 miles

Learn More »